Gilead and Novo Nordisk expand collaboration in NASH therapeutics

  • Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis ('NASH").
  • The two companies have agreed to conduct a Phase 2b study to investigate the safety and efficacy of Novo Nordisk 's semaglutide.
  • The double-blind, placebo-controlled study in patients with compensated cirrhosis due to NASH will evaluate the GLP-1 receptor agonist alone and in combination with a fixed-dose combination of Gilead Sciences 's investigational therapies, FXR agonist cilofexor, and ACC inhibitor firsocostat.
  • With the recruitment of ~440 subjects starting in H2 2021, the trial will evaluate the therapeutics' effect on liver fibrosis improvement and NASH resolution.
  • The new mid-stage study builds on a positive Phase 2a proof-of-concept study for semaglutide in patients with NASH. Its results were presented at the Liver Meeting Digital Experience in November 2020.

    Over the current book year the total revenue from the company in Foster City will be 24.79 billion USD (consensus estimates). This is slightly more than 2020's revenue of 24.69 billion USD.

    Historical revenues and results Gilead Sciences plus estimates 2020


    The analysts expect for 2021 a net profit of 9.02 billion USD. The majority of the analysts expects for this year a profit per share of 7.17 USD. Based on this the price/earnings-ratio is 8.92.

    Huge dividend Gilead Sciences

    Per share the analysts expect a dividend of 2.74 USD per share. Thus the dividend yield equals 4.28 percent. The average dividend yield of the biotech companies is a moderate 0.37 percent.

    Most recent target prices around 73 USD

    The most recent recommendations for the biotech company are from Morgan Stanley , RBC Capital Markets and Credit Suisse .

    Based on the current number of outstanding shares Gilead Sciences 's market capitalization 81.01 billion USD. The Gilead Sciences stock was the past 12 months quite unstable. Since last March the stock is 10 percent lower. This year the stock price moved between 57 and 86 dollar.

    Price data Gilead Sciences 2007-2021

    stock prices gileadsciences

    Click here for dividend Gilead Sciences. On Thursday the stock closed at 63.99 USD. Nieuwsdienst: +31 084-0032-842

    Copyright B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.